NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Short Interest Update

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 38,703 shares, a growth of 219.1% from the July 15th total of 12,127 shares. Based on an average daily trading volume, of 34,041 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.5% of the company’s shares are short sold.

Insider Transactions at NeuroOne Medical Technologies

In other NeuroOne Medical Technologies news, Director Mark Christianson sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the transaction, the director owned 20,692 shares in the company, valued at approximately $65,800.56. This trade represents a 32.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Hedge funds have recently bought and sold shares of the stock. Legato Capital Management LLC bought a new position in NeuroOne Medical Technologies in the fourth quarter valued at approximately $34,000. Squarepoint Ops LLC bought a new stake in shares of NeuroOne Medical Technologies during the fourth quarter worth $36,000. Susquehanna International Group LLP bought a new stake in shares of NeuroOne Medical Technologies during the third quarter worth $47,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies during the second quarter worth $51,000. Finally, BlackRock Inc. bought a new stake in NeuroOne Medical Technologies in the 2nd quarter valued at $76,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NMTC has been the subject of a number of analyst reports. LADENBURG THALM/SH SH boosted their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings upgraded shares of NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $11.67.

NeuroOne Medical Technologies Stock Performance

NMTC stock traded up $0.28 during midday trading on Thursday, hitting $1.80. 212,478 shares of the company’s stock were exchanged, compared to its average volume of 45,380. NeuroOne Medical Technologies has a one year low of $1.42 and a one year high of $6.96. The company has a market cap of $15.63 million, a PE ratio of -2.11 and a beta of 0.61. The stock’s fifty day moving average price is $2.60 and its 200-day moving average price is $3.82.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.30. The company had revenue of $1.97 million during the quarter, compared to the consensus estimate of $2.55 million. NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%. On average, analysts expect that NeuroOne Medical Technologies will post -0.36 EPS for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.